-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, E3w2wVU3v+yF5UK6osDVOQ6zNS2tYqL/lkvmc386nxJ7VVC4EPho2I/Ecz5YHCWZ 2bb2W62db3nBnTMzB5CqZQ== 0001131399-04-000085.txt : 20040629 0001131399-04-000085.hdr.sgml : 20040629 20040629140406 ACCESSION NUMBER: 0001131399-04-000085 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040629 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-50905 FILM NUMBER: 04888041 BUSINESS ADDRESS: STREET 1: ONE MALCOLM AVE CITY: TETERBORO STATE: NJ ZIP: 07608 BUSINESS PHONE: 2013935000 MAIL ADDRESS: STREET 1: ONE MALCOLM AVE CITY: TETERBORO STATE: NJ ZIP: 07601 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC CENTRAL INDEX KEY: 0001131399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS BUSINESS PHONE: 011442080475000 MAIL ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS SC 13D/A 1 a040629body1.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. 3) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Quest Diagnostics Incorporated - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $.01 Par Value - -------------------------------------------------------------------------------- (Title of Class of Securities) 74834L 10 0 - -------------------------------------------------------------------------------- (CUSIP Number) Donald F. Parman, GlaxoSmithKline One Franklin Plaza, Philadelphia, PA 19102 Telephone 215-751-7633 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 25, 2004 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /. Check the following box if a fee is being paid with the statement / /. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). This Amendment No. 3 amends and supplements the Statement of Schedule 13D electronically filed with the Securities and Exchange Commission (the "Commission") on August 25, 1999 (the "Initial Statement"), and subsequent amendments filed electronically with the Commission on May 14, 2001 and May 22, 2002. The undersigned hereby amends and supplements Items 2 and 5 of the Initial Statement to include the following information (capitalized terms used herein without definition shall have the same meaning as set forth in the Initial Statement). SCHEDULE 13D CUSIP NO. 74834L100 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON GlaxoSmithKline plc - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* OO - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) / / - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION England and Wales - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF SHARES BENEFICIALLY ----------------------------------------------------------------- OWNED BY 8 SHARED VOTING POWER EACH REPORTING 20,952,154 PERSON ----------------------------------------------------------------- WITH 9 SOLE DISPOSITIVE POWER ----------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 20,952,154 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 20,952,154 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 20.5% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! Item 1. Security and Issuer. Item 2. Identity and Background. (a) (b) (c) Set forth in Schedule I to this Amendment ("Schedule I") are the names, business address and present principal occupation or employment of each executive officer and director of the Company. (d) During the last five years, there have been no criminal proceedings against the Company or, to the best knowledge of the Company, any of the other persons with respect to whom information is given in response to this Item 2. (e) During the last five years, neither the Company nor, to the best knowledge of the Company, any of the other persons with respect to whom information is given in response to this Item 2 has not been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to Federal or State securities laws or finding any violation with respect to such laws. (f) The citizenship of each executive officer and director of the Company is set forth in Schedule I. Item 3. Source and Amount of Funds or Other Consideration. Item 4. Purpose of Transaction. Item 5. Interest in Securities of the Issuer. (a) Amount and Percent Beneficially Owned Registered Name No. of Shares Percent SmithKline Beecham Corporation 20,952,154 20.5% (b) (c) On June 25, 2004, the Company sold 1,176,518 shares to the Issuer for $86.13 per share. (d) (e) Item 6. Contracts, Arrangements, Understandings or Relationship With respect to Securities of the Issuer. Item 7. Materials to be Filed as Exhibits. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in the Statement is true, correct and complete. DATED: June 29, 2004 GLAXOSMITHKLINE PLC By: S.M. BICKNELL Company Secretary SCHEDULE I Principal Occupation Name Business Address or Employment Citizenship Board of Directors Dr. Jean-Pierre Garnier One Franklin Plaza Chief Executive French/USA Philadelphia, PA Officer 19102 John D. Coombe 980 Great West Road Chief Financial British Brentford Officer Middlesex England TW8 9GS Dr. Tadataka Yamada 709 Swedeland Road Executive Director USA King of Prussia, PA Chairman Research 19406 and Development Sir Christopher Hogg Reuters Holdings plc Company Director British 85 Fleet Street London, England EC4P 4AJ Sir Crispin Davis Reed Elsevier Group Company Director British plc 1-3 Strand London, England WC2N 5JR Sir Peter Job 980 Great West Road Company Director British Brentford Middlesex England TW8 9GS Sir Ian Prosser 980 Great West Road Company Director British Brentford Middlesex England, TW8 9GS Dr. Lucy Shapiro Stanford University Company Director USA School of Medicine Beckman Center, B300 279 Campus Drive Stanford, California 94305-5329 Lawrence Culp Danaher Corporation Company Director USA 2099 Pennsylvania Avenue, 12th Floor, Washington DC20006 Sir Christopher Gent 980 Great West Road Company Director British Brentford Middlesex England, TW8 9GS Sir Deryck Maughan Citigroup Company Director British 399 Park Avenue New York NY 10022 Dr. Ronaldo Schmitz Deutsche Bank Company Director German Taununsanlage 12 D-62062 Frankfurt Germany Sir Robert Wilson 24 Edwards Square Company Director British London England, W8 6HH GlaxoSmithKline Corporate Executive Team Dr. Jean-Pierre Garnier One Franklin Plaza Chief Executive French/USA Philadelphia, PA Officer 19102 John D. Coombe 980 Great West Road Chief Financial British Brentford Officer Middlesex England TW8 9GS Rupert M. Bondy 980 Great West Road Senior Vice British Brentford President and Middlesex General Counsel England TW8 9GS Ford Calhoun One Franklin Plaza Chief Information USA Philadelphia, PA Officer 19102 Marc Dunoyer GSK Building President French 6-15, Sendagaya Pharmaceuticals 4 chome,Shibuya-ku Japan Tokyo 151-8566 Russell Greig 980 Great West Road President British Brentford Pharmaceuticals Middlesex International England, TW8 9GS Daniel J. Phelan One Franklin Plaza Senior Vice USA Philadelphia, PA President 19102 Human Resources David Pulman Five Moore Drive President British PO Box 13398 Global Manufacturing Research Triangle & Supply Park, North Carolina 27709 David M. Stout One Franklin Plaza President USA Philadelphia, PA Pharmaceutical 19102 Operations Christopher Viehbacher Five Moore Drive President German/ PO Box 13398 US Pharmaceuticals Canadian Research Triangle Park North Carolina 27709 Andrew Witty 980 Great West Road President British Brentford Pharmaceuticals Middlesex Euorpe England, TW8 9GS Dr. Tadataka Yamada 709 Swedeland Road Executive Director USA King of Prussia, PA Chairman Research 19406 and Development Jennie Younger 980 Great West Road Senior Vice British Brentford President Corporate Middlesex Communications & England, TW8 9GS Community Partnerships Jack Ziegler One Franklin Plaza President USA Philadelphia, PA Consumer Healthcare 19102 -----END PRIVACY-ENHANCED MESSAGE-----